---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-008633"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2025-06-16T23:59:59+00:00"
generated_at: "2026-05-19T06:34:40.952316+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NextCure licenses ADC SIM0505 from Simcere Zaiming in deal worth up to $745M

## Summary
- Upfront cash $12M + $5M payable upon financing or by Dec 31, 2025; milestones up to $745M plus tiered royalties up to double digits.
- Private placement: Simcere affiliate buys 4,063,633 shares at $0.492/share for $2M; registration rights granted.
- SIM0505 (CDH6-targeting ADC) in Phase 1 in China; US Phase 1 expected Q3 2025 with initial data in H1 2026.
- NextCure also obtains non-exclusive license to Simcere's linker/payload for a novel target ADC; Simcere retains Greater China rights.
- Cash runway into mid-2026 based on current resources; company expects to exhaust sooner if assumptions prove incorrect.

## SEC filing metadata
- accession: 0001558370-25-008633
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2025-06-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837025008633/0001558370-25-008633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837025008633/nxtc-20250613x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-008633
- JSON: https://secwatch.observer/filing/0001558370-25-008633.json
- Plain text: https://secwatch.observer/filing/0001558370-25-008633.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.